Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF V600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Titel:
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF V600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Auteur:
Zimmer, Lisa Livingstone, Elisabeth Krackhardt, Angela Schultz, Erwin S. Göppner, Daniela Assaf, Chalid Trebing, Dietrich Stelter, Kai Windemuth-Kieselbach, Christine Ugurel, Selma Schadendorf, Dirk